BPC 157 with TB 500 Dosing for Tendon Repair

Posted by coldmind64 in Dosing and Protocols

Hey everyone, I'm doing some research on tendon repair and looking into BPC 157 and TB 500. I've seen a lot of anecdotal reports about their synergistic effects, which is really interesting from a research perspective. I'm trying to optimize a protocol for a study I'm designing. Specifically, I'm curious about the optimal dosing and administration frequency when using both compounds together. Are there any established research protocols or even well documented personal research logs that detail a combined approach for tendon healing? I'm looking for specifics on dosage per kg if possible, and how often each compound was administered. My current thoughts are around 250mcg of BPC 157 and 500mcg of TB 500 daily, but I'm unsure if this is too high or too low for a combined approach. I'm also considering subcutaneous versus intramuscular for each, and if there's a benefit to splitting doses. Any insights or references to studies would be greatly appreciated. I want to ensure my research is as robust as possible. Remember, this is all for research purposes only, not for human consumption.

6 Comments

amberfiles

I've seen some protocols suggesting a higher initial loading phase for TB 500, like 1mg twice a week for a few weeks, then dropping to 500mcg. Have you looked into that?

titration_pdx44

From my research, 250mcg BPC 157 daily and 500mcg TB 500 twice a week seems to be a common starting point for combined studies. Subcutaneous is often preferred for ease of administration.

echo88

I've seen some researchers split the BPC 157 dose into two smaller administrations per day, morning and evening, to maintain more stable levels. Any thoughts on that for combined use?

coldmind64

That's interesting about the TB 500 loading phase. Do you recall if those protocols also adjusted the BPC 157 dose during that time, or did it remain consistent?

amberfiles

From what I remember, the BPC 157 dose usually stayed consistent at around 250mcg daily. The focus of the loading phase was primarily on saturating the TB 500 receptors, so to speak.

clinicalhead

Splitting the BPC 157 dose makes sense for a more sustained presence, especially with its shorter half life compared to TB 500. For research, it might offer a more consistent therapeutic window.